The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
Open accessAbstract
OBJECTIVE: To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D), documented pre-existing cardiovascular disease (CVD), and a history of hypertension. RESEARCH DESIGN AND METHODS: Patients (N = 922) were randomized to receive 10 mg dapagliflozin or placebo in a double-blind trial for 24 weeks, followed by a 28-week extension period. In patients receiving insulin, the insulin dose was reduced by 25% at randomization. Patients were stratified by age, insulin use, and time from the most recent qualifying cardiovascular (CV) event. Co-primary end points were a change from baseline in hemoglobin A1c (HbA1c) and the proportion of patients achieving a combined reduction in HbA1c of ≥0.5% (5.5 mmol/mol), body weight (BW) of ≥3%, and systolic blood pressure (SBP) of ≥3 mmHg. RESULTS: At 24 weeks, dapagliflozin significantly reduced HbA1c (−0.38% [−4.2 mmol/mol]) from baseline (8.18%) compared with a slight increase with placebo from baseline (8.08%) (0.08% [0.9 mmol/mol]). Significantly more patients met the three-item end point with treatment with dapagliflozin than with placebo (11.7% vs. 0.9%, respectively). Changes were maintained over 52 weeks. Although ∼42% of patients were ≥65 years old, similar results were observed in both age-stratified groups. Serious adverse events, hypoglycemia, urinary tract infections, and cardiac disorders were similar between groups. Adverse events of hypotension, dehydration, hypovolemia, genital infection, and renal failure or impairment occurred more often with dapagliflozin treatment. CONCLUSIONS: In this study that evaluated T2D patients who were at high risk for future CVD events, dapagliflozin administration had significantly greater effects in reducing HbA1c, BW, and SBP, without adversely impacting CV safety when compared with placebo treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The addition of metabolic surgery (148), weight loss medications (149), and glucose-lowering agents that promote weight loss (150) can also be used as an adjunct to lifestyle interventions, resulting in greater weight loss that is maintained for a longer period of time.”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [150]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 860
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Nauck, M. A., Del Prato, S., Meier, J. J., Durán-García, S., Rohwedder, K., Elze, M., & Parikh, S. J. (2011) · Diabetes Care · doi:10.2337/dc11-0606 · Cited by 528
Self-citationStrojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 406
Self-citationWilding, J. P. H., Norwood, P., T'joen, C., Bastien, A., List, J. F., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc09-0517 · Cited by 363
Tsiatis, A. A., Davidian, M., Zhang, M., & Lu, X. (2008) · Statistics in Medicine · doi:10.1002/sim.3113 · Cited by 349 · cited 1×
“The primary end points were tested by an ANCOVA model and the Cochran-Mantel-Haenszel method, respectively (13).”
MethodDiabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006
Cheung, B. M. Y., Ong, K. L., Cherny, S. S., Sham, P.-C., Tso, A. W. K., & Lam, K. S. L. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.047 · Cited by 348
Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
Geerlings, S., Fonseca, V., Castro-Diaz, D., List, J., & Parikh, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.052 · Cited by 274
Self-citationVulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
Johnsson, K. M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S. J., & List, J. F. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.012 · Cited by 213
Self-citationAdverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3
Berlin, J. A., Glasser, S. C., & Ellenberg, S. S. (2008) · American Journal of Public Health · doi:10.2105/ajph.2007.124537 · Cited by 206
Urinary tract infections in patients with diabetes treated with dapagliflozin
Johnsson, K. M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S. J., & List, J. F. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.05.004 · Cited by 205
Self-citationLeiter, L. A., Cefalu, W. T., de Bruin, T. W. A., Gause‐Nilsson, I., Sugg, J., & Parikh, S. J. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12881 · Cited by 182 · cited 3×
“Safety results were largely similar for the current study and the companion study (15).”
ResultInfluentialSelf-citationSGLT2 inhibitors in the treatment of type 2 diabetes
Hasan, F. M., Alsahli, M., & Gerich, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.02.014 · Cited by 173 · cited 1×
“study, along with its sister comparison trial, provided data on efficacy and weight loss in a high-risk group of patients, which separates this study from others (27).”
ResultZhang, L., Feng, Y., List, J., Kasichayanula, S., & Pfister, M. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01216.x · Cited by 171
Efficacy of Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes Mellitus: A Meta-analysis
Norris, S. L., Zhang, X., Avenell, A., Gregg, E. W., Schmid, C. H., Kim, C., & Lau, J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1395 · Cited by 159
Horton, E. S., Silberman, C., Davis, K. L., & Berria, R. (2010) · Diabetes Care · doi:10.2337/dc09-2062 · Cited by 156
Ptaszynska, A., Johnsson, K. M., Parikh, S. J., de Bruin, T. W., Apanovitch, A. M., & List, J. F. (2014) · Drug Safety · doi:10.1007/s40264-014-0213-4 · Cited by 138 · cited 3×
“Moreover, in a meta-analysis (26) for major adverse cardiac events (i.”
BackgroundInfluentialSelf-citationKasichayanula, S., Liu, X., Benito, M. P., Yao, M., Pfister, M., LaCreta, F. P., Humphreys, W. G., & Boulton, D. W. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12056 · Cited by 121 · cited 1×
“These data appear to be in contrast to those from a report (16) suggesting reduced efficacy in patients with moderate renal impair-”
ResultTreatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999–2004
Dodd, A. H., Colby, M. S., Boye, K. S., Fahlman, C., Kim, S. W., & BRIEFEL, R. R. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902973300 · Cited by 91
Jabbour, S. A., Whaley, J. M., Tirmenstein, M. A., Poucher, S. M., Reilly, T. P., Boulton, D. W., Saye, J. A., List, J. F., & Parikh, S. J. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2569 · Cited by 16 · cited 1×
“Urinary frequency was not evaluated in this study, although early work on the compound (21) did demonstrate an in-”
ResultSelf-citation
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Hsia, D. S., Grove, O., & Cefalu, W. T. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000311 · Cited by 508
Self-citationZaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., & Davies, M. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 489
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s005 · Cited by 445
Metadata
- Authors
- Cefalu, W. T., Leiter, L. A., de Bruin, T. W. A., Gause-Nilsson, I., Sugg, J., & Parikh, S. J.
- Affiliations
- Pennington Biomedical Research Center (US)
- St. Michael's Hospital (CA)
- AstraZeneca, Global Medicines Development, Gaithersburg, MD
- AstraZeneca, Global Medicines Development, Mölndal, Sweden
- AstraZeneca (United States) (US)
- Corresponding author
- Cefalu, William T.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-04-07
- Volume
- 38
- Issue
- 7
- Pages
- 1218-1227
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4831907
- OpenAlex
- W2076506641
- Cited by
- 182
- References
- 29
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 24 · 2023: 12 · 2022: 15 · 2021: 20 · 2020: 10 · 2019: 16 · 2018: 14 · 2017: 17 · 2016: 20 · 2015: 5
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Intarcia Therapeutics
- MannKind Corporation
- Halozyme
- Novo Nordisk
- Servier
- National Institutes of Health
- National Institute of General Medical Sciences (104940, GM104940, U54GM104940)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, glycemic control, cardiovascular risk, hypertension, HbA1c, weight loss, systolic blood pressure, insulin dose reduction, adverse events, renal failure, urinary tract infection, older adults, cardiovascular safety, high-risk patients, hypoglycemia
- MeSH terms
- Analysis of Variance, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Urinary Tract Infections, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.